RxDoctor Payments Data

Qing Ni, MD

Neurology · Newnan, GANPI 1295765311

Payments from drug & device makers

$42,082in general payments, 2019–2025

Across 1,309 payments — averaging $32.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$12K
  • SK Life Science, Inc.$6K
  • AbbVie$4K
  • UCB, Inc.$2K
  • Upsher-smith Laboratories LLC$1K
  • AstraZeneca$985
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$4,05010%
  • Speaking & faculty fees$12,26229%
  • Travel & lodging$1,3553%
  • Food & beverage$24,05557%
  • Education$3601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.34$12,052
SK Life Science, Inc.53$5,559
AbbVie(2 entities)107$3,807
UCB, Inc.100$1,785
Upsher-smith Laboratories LLC81$1,004
AstraZeneca(2 entities)31$985
Teva Pharmaceuticals USA, Inc.44$893
Jazz Pharmaceuticals Inc.24$785
Novartis49$748
Neurelis, Inc.38$722
Pfizer49$692
Lilly USA, LLC38$667
Scilex Pharmaceuticals Inc.42$638
Sunovion Pharmaceuticals Inc.43$626
MDD US Operations, LLC27$597
Eisai Inc.25$584
Lundbeck LLC25$581
Biogen32$524
Neurocrine Biosciences, Inc.21$502
Avanir Pharmaceuticals, Inc.27$502
Acadia Pharmaceuticals Inc25$472
Supernus Pharmaceuticals, Inc.39$471
Greenwich Biosciences, Inc.19$456
Otsuka America Pharmaceutical, Inc.17$434
EMD Serono, Inc.10$391
Axsome Therapeutics, Inc.17$386
Harmony Biosciences LLC16$347
Kyowa Kirin, Inc.19$342
Sanofi20$318
Amneal Pharmaceuticals LLC20$304
Argenx US, Inc.14$287
Azurity Pharmaceuticals, Inc.16$271
Amgen(2 entities)16$266
Adamas Pharmaceuticals, Inc.17$262
Takeda Pharmaceuticals U.S.A., Inc.13$240
CSL Behring13$210
Biohaven Pharmaceutical Holding Company Ltd.13$188
Genentech USA, Inc.11$185
ANI Pharmaceuticals, Inc.8$184
Mallinckrodt Hospital Products Inc.9$173
Currax Pharmaceuticals LLC10$163
Grifols USA, LLC8$135
Akcea Therapeutics, Inc.1$126
Arbor Pharmaceuticals, Inc.8$125
Johnson & Johnson3$117
Acorda Therapeutics, Inc7$109
Avion Pharmaceuticals5$94
TG Therapeutics, Inc.4$80
Impel Pharmaceuticals Inc.4$68
Neuronetics, Inc.3$63
Bausch Health US, LLC3$55
Zyla Life Sciences, Inc.3$47
Vertical Pharmaceuticals, LLC3$46
Vanda Pharmaceuticals Inc.3$40
Aquestive Therapeutics, Inc.2$36
Promius Pharma LLC2$34
Corium, LLC2$31
GE HealthCare2$30
Alnylam Pharmaceuticals Inc.2$30
Banner Life Sciences, LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,082 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$226,832
Medicare patients
575
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5026$356,967
AustedoDeutetrabenazine29$319,795
Austedo XrDeutetrabenazine27$279,590
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$272,909
IngrezzaValbenazine Tosylate21$171,644
NuplazidPimavanserin Tartrate26$133,918
BriviactBrivaracetam50$75,497
CopaxoneGlatiramer Acetate13$74,599
Nurtec OdtRimegepant Sulfate49$58,560
QuliptaAtogepant38$40,182
XcopriCenobamate21$36,934
EpidiolexCannabidiol (Cbd)12$28,259
XadagoSafinamide Mesylate24$26,634
RytaryCarbidopa/Levodopa46$22,414
FycompaPerampanel22$20,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Copaxone$893$673,98369 claims
PfizerOctagam, Nurtec Odt, Eliquis$692$431,462100 claims
Grifols USA, LLCGamunex-C$135$272,90924 claims
Neurocrine Biosciences, Inc.Ingrezza$502$171,64421 claims
Acadia Pharmaceuticals IncNuplazid$472$133,91826 claims
UCB, Inc.Briviact, Nayzilam$1,785$84,26963 claims
AbbVieQulipta, Namzaric$3,807$47,66451 claims
SK Life Science, Inc.Xcopri$5,559$36,93421 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$304$27,03181 claims
Eisai Inc.Fycompa$584$20,93622 claims
Scilex Pharmaceuticals Inc.Ztlido$638$14,82619 claims
Sunovion Pharmaceuticals Inc.Aptiom$626$14,07311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →